Quest Diagnostics二季度业绩超预期并上调全年指引，但原文标题混入Tesla下跌信息

Tesla slumps 10% after earnings miss on softer automotive margins
Introduction & Market Context
Quest Diagnostics (NYSE:DGX) presented strong second-quarter 2026 results on July 23, 2026, showcasing double-digit revenue growth and raising its full-year outlook as demand remained robust across physician, hospital, and consumer channels. The company’s shares surged more than 11% in premarket trading to $233.22, approaching the 52-week high of $237.70, after reporting adjusted earnings per share of $3.12 that beat analyst expectations of $2.82 by 10.6%.
Total revenue reached $3.04 billion in the quarter, representing a 10.2% increase from the prior year, with nearly all growth coming from organic sources. The performance prompted management to raise 2026 revenue guidance to $11.95 billion to $12.05 billion and adjusted diluted EPS guidance to $11.05 to $11.25, up from prior ranges of $11.78 billion to $11.90 billion and $10.63 to $10.83, respectively.
Quarterly Performance Highlights
As shown in the company’s Q2 2026 performance overview, Quest delivered impressive top- and bottom-line growth across multiple metrics. Adjusted operating income reached 16.5% of net revenues, while adjusted diluted EPS of $3.12 per share grew 19.1% year-over-year, significantly outpacing revenue growth.
The quarter’s performance was driven primarily by volume expansion rather than pricing. Total requisition volume increased 13.1% year-over-year, with organic volume up 13.0%, demonstrating strong underlying demand for diagnostic services. Revenue per requisition declined 2.8%, though management noted this was largely due to mix effects from the Fresenius Medical Care and Corewell Health partnerships. Excluding these mix impacts, revenue per requisition actually increased 2.9%.
"Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health," said Jim Davis, Chairman, CEO, and President. "With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance."
Detailed Financial Analysis
Quest’s revenue growth trajectory has shown consistent acceleration over recent quarters. The following chart illustrates how Q2 2026’s 10.2% total revenue growth was almost entirely organic, with growth spanning physician, hospital, and consumer channels.
The company’s diagnostic information services revenues grew 10.3% to $2.978 billion, representing 98% of total revenues. This growth was supported by broad-based volume increases across customer segments, as evidenced by the 13.1% jump in total requisitions.
The relationship between volume growth and revenue per requisition reveals important operational dynamics. While volume surged 13.1%, revenue per requisition fell 2.8%, primarily reflecting the addition of lower-price-point services through hospital partnerships. The following chart demonstrates these trends over multiple quarters.
Chief Financial Officer Sam Samad highlighted that tests per requisition have become a major growth driver, noting that the metric has increased from 3.5-4.0 tests per requisition before COVID to nearly 4.5 currently, reflecting greater test utilization and more comprehensive diagnostic panels.
Operating performance remained solid despite some margin pressure. Reported operating income reached $459 million, or 15.1% of net revenues, compared to $438 million, or 15.9%, in the prior year. On an adjusted basis, operating income was $502 million, or 16.5% of revenues, versus $466 million, or 16.9%, a year earlier. The 40-basis-point decline in adjusted operating margin reflects higher costs from strategic initiatives and the mix impact from recent partnerships.
The company’s payer mix has remained relatively stable, providing diversified revenue streams. The following chart shows the breakdown of quarterly net revenues by payer customer type.
In Q2 2026, healthcare insurers represented 37% of revenues (35% fee-for-service, 2% capitated), government payers 16%, client payers 32%, and direct patient payments 13%. This balanced mix helps insulate Quest from changes in any single payer category.
Quest’s business model centers on two primary customer channels and multiple service lines. The company’s 2025 revenue breakdown, which provides context for the current quarter’s performance, shows the strategic focus areas.
Physician lab services accounted for 71% of 2025 revenues, with hospital lab services contributing 18%. From a service perspective, routine clinical testing represented 54% of revenues, while higher-value gene-based and esoteric testing services comprised 38%, and anatomic pathology 6%. The substantial portion of advanced diagnostics positions Quest for continued growth as healthcare moves toward more personalized and precision medicine.
Strategic Initiatives
Quest highlighted several key strategic developments during the quarter that position the company for sustained growth. The collaboration with Fresenius Medical Care has developed new kidney care capabilities for nephrologists, dialysis centers, and patients, expanding Quest’s presence in the chronic disease management space.
The company received New York State approval for its Haystack MRD™ test, making it one of few solid tumor circulating tumor DNA minimal residual disease tests to meet the state’s rigorous quality criteria. This approval is significant as New York maintains some of the strictest laboratory standards in the nation, and the test addresses the growing oncology diagnostics market.
Quest also launched IntelliDraw™, a tool designed to guide physician customers’ clinical staff through the specimen collection process. This innovation aims to improve quality and service by reducing collection errors and improving the patient experience.
Management emphasized the role of automation and artificial intelligence in driving operational improvements. CEO Davis stated these tools are enabling "continuous improvements in quality and productivity both in and outside our labs," suggesting ongoing margin expansion opportunities as these technologies scale.
Forward-Looking Statements
Quest’s updated full-year 2026 guidance reflects confidence in sustained momentum through year-end. The following comparison shows how the company raised its outlook across key metrics.
The revenue guidance increase of approximately $170 million at the midpoint represents an 8.3% to 9.2% growth rate for the full year. Adjusted diluted EPS guidance was raised by $0.42 at the midpoint, reflecting both higher revenue expectations and continued operational leverage.
Management outlined several assumptions underlying the updated guidance. The revenue outlook does not incorporate contributions from prospective mergers and acquisitions. Project Nova expenses, related to the company’s technology transformation initiative, remain unchanged for the full year but with increased spending anticipated in the second half compared to prior expectations. Higher fuel costs are also expected in the second half of 2026.
Despite these headwinds, Quest expects operating margin to expand versus the prior year, supported by volume growth and operational efficiencies. The company anticipates share count will be slightly below 2025 levels, interest expense consistent with 2025, and the adjusted effective tax rate in line with the prior year.
Management also noted an expected 30-basis-point revenue impact from the expiration of Affordable Care Act exchange subsidies, with effects more concentrated in the second half of the year. However, the company indicated that while ACA exchange enrollment fell approximately 21% year-over-year, test volume from that population declined only about 2%, as healthier individuals left the exchanges while patients with greater healthcare needs remained.
Market Reaction and Analyst Perspectives
The market’s strong positive reaction to Quest’s results and raised guidance suggests investors view the company’s growth trajectory as sustainable and supported by fundamental demand rather than temporary factors. The 11.15% premarket gain brought shares to $233.22, leaving them just 1.9% below the 52-week high.
The combination of a 10.6% earnings beat, revenue exceeding expectations by $70 million, and a meaningful guidance increase represents a trifecta that typically drives significant revaluation. According to InvestingPro, Quest maintains a "GREAT" Financial Health Score, with particularly strong profit and price momentum scores, though the stock may be trading above fair value estimates at a P/E ratio of 22.8.
Analysts focused questioning on the hospital partnership pipeline, margin pressure, and reimbursement policy during the earnings call. Management indicated the hospital business remains strong with a healthy pipeline of potential deals, particularly with growing health systems. On margins, Quest acknowledged second-half cost pressures from Nova spending and fuel but expects volume growth and easier year-over-year comparisons to help offset these headwinds.
The company continues to advocate for passage of the RESULTS Act, which would reform how Medicare sets laboratory payment rates under the Protecting Access to Medicare Act (PAMA). Management outlined three possible policy outcomes: a CMS data collection process, passage of the RESULTS Act, or another delay in implementation.
With 2025 revenues of $11.04 billion, Quest serves 50% of U.S. hospitals and physicians through nearly 60,000 employees across Quest and its LifeLabs subsidiary. The company’s scale, combined with strategic investments in advanced diagnostics and operational technology, positions it to capitalize on the ongoing shift toward more comprehensive and personalized diagnostic testing in healthcare.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.